Aims It is not known whether the apparent normality of echocardiographic examination results, in subjects bearing a mutation for hypertrophic cardiomyopathy but without ultrasonic left ventricular hypertrophy, is due to incomplete phenotypic expression, or inaccurate echocardiographic criteria. The aim of this study was to search for echocardiographic abnormalities in these patients.
Introduction
Familial hypertrophic cardiomyopathy is inherited in an autosomal dominant pattern and the genetic heterogeneity of the disease has been established [1, 2] . Linkage analysis has shown that in about one third of the kindreds, a mutation in the -myosin heavy chain ( -MHC) gene can be demonstrated on chromosome 14q [3, 4] ; other genes have been identified on chromosomes 1 (encoding for cardiac troponin T), 15 (encoding for -tropomyosin), and 11 (encoding for the cardiac myosin binding My-BPC) [5] [6] [7] [8] [9] [10] , but some families are not linked to any of these loci [11, 12] . Echocardiographic left ventricular hypertrophya cornerstone of hypertrophic cardiomyopathy diagnosis when secondary causes of left ventricular hypertrophy have been eliminated -proved to be an imperfect test for familial screening: until adolescence, the disease is usually not evident from echocardiographic assessment, and in adults the mutation is markedly more prevalent in some kindreds than is indicated by echocardiography [13] [14] [15] [16] [17] [18] [19] . Thus, when based on echocardiographic left ventricular hypertrophy, the disease penetrance is highly variable with the causal mutation [6, [14] [15] [16] [17] [18] [19] [20] [21] [22] [23] [24] [25] . However, it is not known whether the apparent normality of the echocardiographic examination in some subjects who are carriers of a gene mutation is due to incomplete phenotypic expression or to the lack of accuracy of accepted echocardiographic criteria. The aim of this study was to search for echocardiographic structural and functional abnormalities in genetically affected subjects who presented no evidence of ultrasonic ventricular hypertrophy.
Methods

Population study
Among the genotyped families with hypertrophic cardiomyopathy in France, we studied two caucasian families (714 and 720) with a high frequency of subjects carrying the abnormal gene but with an apparently normal heart by echocardiography. None of these subjects, except one affected person -an 82-year-old female with marked asymetric left ventricular hypertrophy in Family 720 -presented with systemic hypertension. One genotypically affected subject (Family 720) without hypertrophy but with a dilated (59 mm) hypokinetic left ventricle was considered as echocardiographically affected, despite absence of increased wall thickness (11 mm) and was excluded from the analysis. Thus, 100 affected subjects and first-degree relatives -73 in Family 714 and 27 in Family 720 -were included in the study after having obtained informed consent; there were 39 genetically affected subjects (including three children <18 years old) and 61 genetically unaffected subjects (including four children) ( Table 1) ; none of them had undergone cardiac surgery or pacemaker implantation and all were in sinus rhythm.
Genetic analysis
Genotypic assessments were obtained from family members using amplification, polymerase chain reaction, microsatellite typing and sequencing techniques, as previously described [9, 10, 19] . Individual subjects were determined to be genetically affected on the basis of the presence of a missense Arg 403 Leu mutation of the -MHC gene on chromosome 14q11-q12 (Family 720), or of a splice acceptor site 'SASint(A<G) mutation on the My-BPC gene on chromosome 11p11 (Family 714) [9, 10, 19, 26] .
Echocardiographic analysis
Two-dimensional echocardiographic examinations were performed in three separate institutions with standard echocardiographic systems. Ultrasonic images were obtained in cross-sectional planes using standard transducer positions: parasternal long-axis and short-axis views of the left ventricle at the base, papillary muscles and apex levels, apical two-and four-chamber views. All echocardiographic measurements were performed in a core laboratory by three senior echocardiographists who read the recordings blindly and without knowledge of the genetic diagnosis. End-diastolic left ventricular wall thickness measurements were taken at the onset of the QRS complex, using the leading edge method, according to the recommendations of the American Society of Echocardiography [27] and were obtained at separate locations (anterior and posterior septum, anterior, lateral and posterior walls) from the parasternal views; apical views were used to integrate the information obtained in the short-axis images. Measurements from three separate beats were averaged and the maximal left ventricular wall thickness (LVWTmax) from any location was determined; diagnosis of hypertrophic cardiomyopathy was considered when LVWTmax by two-dimensional echocardiography was d13 mm in adults [19, 20] or exceeded the 95% prediction limits of normal, according to the Henry nomograms, in children (<18 year old) [28] . In case of disagreement on the presence of left ventricular hypertrophy (as previously defined), the three readers interpreted the studies by committee and a definitive answer was given.
In subjects without left ventricular hypertrophy by two-dimensional examination (according to the method previously described), M-mode echocardiography -at or just below the tips of the mitral valve leaflets -was used to measure end-systolic and end-diastolic septal and posterior wall thickness and left ventricular dimensions to calculate: (1) the left ventricular ejection fraction using the Teicholz correction of the cube formula [29] ; (2) the body surface area indexed left ventricular mass (LVMi) using the Penn convention [30] ; (3) the endocardial fractional shortening and endsystolic stress using cuff systolic blood pressure recorded at the end of the ultrasonic examination and invasively validated formulae [31, 32] . We also measured: (1) the two-dimensional echocardiography: left atrial dimensions at end-systole using the inner edge to inner edge convention (anteroposterior (LAD) on parasternal long-axis, superoinferior (LAD ) and medio-lateral (LAD) on apical four-chamber views); left atrial volume (LAVol) was calculated as 4/3 LAD/2 LAD /2 LAD/2; (2) A and E wave velocities and their ratio E/A and pulsed wave Doppler examination of mitral inflow at the mitral anulus level; (3) isovolumic relaxation time using Doppler recordings in the high outflow tract; (4) anterior and posterior mitral valve leaflet lengths on parasternal long-axis and apical four-chamber views on enddiastolic images after annular hinge points and leaflets tips were identified by real-time videotape view; for each leaflet, a mean between the two views was performed; these measurements were secondarily adjusted on the mitral annulus dimension as assessed on parasternal long-axis and on LVWTmax; (5) mitral regurgitation was assessed by colour Doppler on a scale of 1 to 4+ by extension in the left atrium.
All measurements were averaged on three consecutive beats. When necessary, adjustments were performed for age, height, body surface area and/or systolic blood pressure.
Statistical analysis
Differences concerning clinical variables between the three groups (genotypically affected with left ventricular hypertrophy, without left ventricular hypertrophy, and unaffected subjects) were assessed using one-way analysis of variance for quantitative variable, and a chi-square test for the sex variable. Differences in mean values between the genotypically affected cohort without left ventricular hypertrophy and the unaffected cohort were compared using the unpaired Student t-test inside each family and for the whole study group. Covariance analysis (using a general linear model) was performed for adjusted comparisons when tests for normality of residuals were satisfied. In Family 714, it was possible to match for sex, age and height each genotypically affected subject without left ventricular hypertrophy with two normal subjects within the same family, except for one affected child who was matched with only one normal; these two cohorts were then compared using a Student t-test. Two-way analysis of variance was used to check if differences between the two cohorts were similar in the two families. The data were expressed as means SD. Statistical significance was obtained when P<0·05.
Inter-observer agreement
Inter-observer variability was assessed for each measurement using the coefficient of correlation and the standard error of estimate (SEE) according to the Bland Altman method. Correlation between measurements were very close for LVWTmax (r=0·98, SEE= 0·7 mm) and for other linear measurements (r>0·98, SEE<1·1 mm). There was a disagreement in only three subjects concerning the presence of left ventricular hypertrophy: after interpretation by committee, two subjects were considered as having left ventricular hypertrophy (one with a normal genotype, one with a mutation) and one subject (with a normal genotype) was finally classified in the normal echocardiographic group.
Results
Genotypically affected subjects with left ventricular hypertrophy: comparison between families
When comparing all subjects or patients genetically affected with left ventricular hypertrophy between the two families, no difference was found for sex ratio, age, systolic blood pressure or degree and asymmetry of hypertrophy (Table 1) ; none of the children had left ventricular hypertrophy.
Clinical comparison between groups
Clinical characteristics were compared between the three groups: genetically unaffected subjects, affected subjects without left ventricular hypertrophy and affected subjects with left ventricular hypertrophy ( Table 2 ): age and weight were different between these three groups but not height, body surface area, blood pressure or sex ratio.
Comparison between genotypically non-affected and affected subjects without left ventricular hypertrophy
Electrocardiographic abnormalities defined [17] as major -pathological Q waves >0·04 s or >1·3 R waves, deep negative T waves or left ventricular hypertrophy defined by a Romhilt-Estes score d4 -or as minorenlarged P waves or left bundle branch block -were found in 50% (10 subjects) of the genetically affected subjects without left ventricular hypertrophy as opposed to only one normal subject (1·6%) (P<0·0001). All genotypically affected subjects without left ventricular hypertrophy were totally asymptomatic, presented normal clinical examination and no overt arrhythmia.
Compared to unaffected subjects, genotypically affected subjects without left ventricular hypertrophy (LVWTmax <13 mm) presented with a significantly greater maximal left ventricular wall thickness, a thicker septum, greater indexed left ventricular mass and lower wall stress (Table 3) . Differences concerning LVWTmax persisted after adjustment for body surface area BSA=body surface area; G=genotypically unaffected subjects; G+, LVH =genotypically affected subjects without LVH; G+, LVH+ =genotypically affected subjects with LVH; SBP=systolic blood pressure. Table 3 Comparison between unaffected subjects and affected subjects without left ventricular hypertrophy
AML=mean anterior mitral leaflet length obtained from the apical four-chamber and long-axis views (mean AML length in unaffected subjects+1·64 SD=29 mm); E/A=peak E on A mitral inflow velocity ratio; ESS=left ventricular end-systolic wall stress; FS=endocardial fractional shortening; G =genotypically unaffected subjects; G+, LVH =affected subjects without LVH; LAD=left atrial antero-posterior dimension; LAVol=left atrial volume; LVDDi=left ventricular end-diastolic dimension (indexed to height); LVEF=left ventricular ejection fraction; LVMi=left ventricular mass (indexed to body surface area); LVSDi=left ventricular end-systolic dimension (indexed to height); LVVolDia=end-diastolic left ventricular volume; LVWTmax=maximal left ventricular wall thickness; LVWTi=maximal left ventricular wall thickness indexed to body surface area; IVRT=left ventricular isovolumic relaxation time; PML=mean posterior mitral leaflet length obtained from the apical four-chamber and long-axis views (mean PML length in unaffected subjects+1·64 SD=14·2 mm).
(P<0·001). When a lower cut-off for left ventricular hypertrophy (c11 mm) was considered, the ventricular wall thickness was similar in the two groups (9·3 vs 8·8 mm, P=0·12), but ventricular mass was significantly greater (106·6 vs 95·9 g . m 2 , P=0·02) while wall stress remained lower (78·4 vs 89·7, P=0·002). Fractional shortening, left ventricular dimensions, E and A velocities, E/A and isovolumic relaxation time were not different in these two groups. None of these subjects had right ventricular hypertrophy.
Mitral valve systolic anterior motion was not observed in affected patients without left ventricular hypertrophy and mitral regurgitation was less than 2+ in all patients. Measurements of anterior and posterior mitral leaflet lengths were possible in 88 and 80 cases, respectively; lengths were not statistically different between genotypically affected subjects without left ventricular hypertrophy and non-affected subjects. When superior ranges for normal values for anterior and posterior mitral leaflets lengths were calculated from values obtained in the non-affected group (as a mean+1·64 standard deviation), all affected patients without left ventricular hypertrophy showed normal anterior leaflet length when compared to unaffected subjects, and only 9·5% had an elongated posterior mitral leaflet. By comparison, elongated anterior and posterior mitral leaflets were found in, respectively, 10 (63%) and seven (37%) patients with a mutation and left ventricular hypertrophy (P<0·001 between these three groups).
Comparison of these echocardiographic parameters was performed in our larger family (714) between genotypically affected subjects without left ventricular hypertrophy and unaffected subjects matched for sex, age and height; the same trends were demonstrated for wall thickness (P=0·04), ventricular mass (P=0·05), wall stress (P=0·02) or atrial volume (P=0·01) even when children were excluded from the analysis (Table 4) .
Similarly, when considering both families, these differences were even more marked after adjustments for height, age and/or systolic blood pressure (Table 5) either for wall thickness (P=0·000003), mass (P=0·005), or left atrial volume (P=0·001); moreover, left ventricular systolic dimension was smaller (P=0·01). Results remained statistically significant when only adults (d18 years) were considered or when a lower cut-off for normal thickness (c11 mm) was chosen (except for ventricular systolic dimension) ( Table 5) .
Two-way analysis of variance demonstrated that the observed differences in cavity dimensions or wall thickness between affected and unaffected subjects were entirely due to a group effect and not a consequence of a family effect (interaction was not statistically significant) either for maximal wall thickness (P=0·04), left ventricular end-systolic dimension (P=0·06) and mass (P=0·05), atrial volume (P=0·04) -even after adjustments for height, age and systolic blood pressure (P<0·01 for each parameter) -or ventricular wall stress (P=0·00002).
Discussion
It is well established that in familial hypertrophic cardiomyopathy some genotypically affected persons have an apparently normal echocardiographic examination and particularly no left ventricular hypertrophy, but that some of them remain at risk of arrhythmia or sudden death [20, 21, 33] . In familial hypertrophic cardiomyopathy, left ventricular wall thickness measured by twodimensional echocardiography may fall within the normal ranges, even when the diagnosis is based on a lower cut-off value than required in sporadic cases (wall thickness d13 mm instead of d15 mm) [14] [15] [16] [17] [18] [19] [20] [21] [22] [23] [24] . The Abbreviations as in Table 3 . Statistical degrees of significance given between brackets concern comparison between subjects d18 year old.
limitations of echocardiographic definitions of hypertrophic cardiomyopathy which fail, even in adults, to identify patients with hypertrophic cardiomyopathy who have inherited a disease gene but who have not developed left ventricular hypertrophy were recently underlined: (1) among 19 individuals carrying a mutation within two families, seven adult patients presented with LVWTmax c11 mm) [19] ; (2) among 65 affected adults (d20 years old) from two -MHC families, 47·7% and 32·3% have a maximum left ventricular wall thickness <15 mm and 13 mm respectively [18] ; (3) in a previous work concerning mutations in the -MHC gene, LVWTmax was less than 14 mm in 44% of the affected patients [22] ; (4) in a large cohort of adult patients with familial hypertrophic cardiomyopathy linked to three distinct morbid genes and several mutations, the sensitivity and negative predictive values of two-dimensional echocardiography for the diagnosis of familial hypertrophic cardiomyopathy were only 61% and 72% respectively [17] . Thus, when based on echocardiographic left ventricular hypertrophy, the disease penetrance varies considerably according to the causal mutation and the cut-off value used for abnormal wall thickness; it varies from about 50% to 100% [6, 14, 22, 23] . According to our echocardiographic criteria for hypertrophic cardiomyopathy (LVWTmax d13 mm), the disease penetrance in living adults carrying the disease gene was only 52% (12/23) and 53·8% (7/13) in Families 714 (My-BPC) and 720 ( -MHC), respectively. As previously noted [25] , the electrocardiogram might help to identify affected adults without hypertrophy when major and minor criteria are taken into account, and in the current study 50% of affected subjects without left ventricular hypertrophy presented with an abnormal ECG.
However, it is still unknown whether these affected subjects without left ventricular hypertrophy have strictly normal echocardiographic parameters. The apparently low phenotypic expression of the disease, as assessed by echocardiographic examination, allowed us to compare a large cohort of genotypically affected subjects without left ventricular hypertrophy with unaffected first-degree relatives. The analysis of these two families linked to distinct morbid genes was justified by the similar morphological appearance of hypertrophic cardiomyopathy in these two kindreds and by the presence of a comparable echocardiographic penetrance. No systematic study has been performed before the present one, which is the first report of a detailed echocardiographic and Doppler evaluation of genotypically affected subjects with apparently normal hearts by echocardiography -i.e. without definite left ventricular hypertrophy -in comparison with first-degree relatives who do not have the disease allele. This type of comparison is justified by the fact that the genetic background in which the mutation occurs may influence the phenotypic expression of hypertrophy [1, 2] . The results observed here are markedly homogeneous: genotypically affected subjects without echocardiographic left ventricular hypertrophy (Fig. 1 ) present differences in echocardiographic examination as compared to genetically unaffected subjects; after adjustment for height, age and systolic blood pressure (Table  5) , they demonstrate greater left ventricular wall thickness, smaller left ventricular cavity size and larger left atrium than non-affected first degree relatives; furthermore, decreased wall stress, despite similar fractional shortening compared to non-affected subjects, suggests a difference in left ventricular pump function [32] . Identification of these subjects without documented left ventricular hypertrophy might have important consequences for pre-clinical diagnosis and therapeutic management in children or adolescents with mutations associated with a poor prognosis, or for physical activity or genetic counselling in adults [1, 2] . The observed difference might be due to the inclusion of some genotypically affected young patients LVWT  0·1  0·2  0·2  0·4  0·03  0·1  0·05  adjusted  0·0006  0·002  0·0005  0·009  0·000003  0·00006  0·00001  LVSD  0·16  0·40  0·20  0·28  0·09  0·25  0·10  adjusted  0·10  0·86  0·008  0·01  0·014  0·10  0·014  LVMi  0·2  0·09  0·2  0·3  0·03  0·02  0·06  adjusted  0·08  0·005  0·03  0·09  0·005  0·005  0·007  LAVol  0·3  0·5  0·3  0·4  0·1  0·2  0·03  adjusted  0·02  0·04  0·2  0·4  0·001  0·004  0·002  ESS  0·02  0·04  0·04  0·04  0·002  0·004  0·01 Results are given before and after adjustment for height, age, systolic blood pressure (LVWT, LVSD, LAVol) or for age and systolic blood pressure (S/P, LVM indexed to body surface area). d18=subjects of 18 years old or more; Both=Family 714+Family 720; ESS=left ventricular end-systolic wall stress; G =non-affected subjects; G+ =affected patients without hypertrophy (LVH<13 mm); LAVol=left atrial volume; LVMi=left ventricular mass (indexed to body surface area); LVSD=left ventricular end-systolic dimension; LVWT=maximal left ventricular wall thickness; WTc11 mm=maximal left ventricular wall thicknessc11 mm.
who are in the process of developing left ventricular hypertrophy [16] ; however, it was suggested that wall thickness does not increase significantly beyond the age of 20 years [22, 34] and results were even more significant when only adults were analysed ( Table 5 ). The choice of an inappropriate cut-off for abnormal wall thickness might have biased the results; however, 13 mm or higher cut-offs were often used in the literature [14, [22] [23] [24] [34] [35] [36] . Moreover, in the current study, when a very low cut-off for normal wall thickness which is strictly within the normal range of values was chosen (c11 mm), the same trends were found. Finally, it has been suggested that cardiac hypertrophy needs to be assessed not by reference to an arbitrary value of left ventricular wall thickness but in the context of the cardiac dimensions of family members who do not have the disease allele [22, 23] ; this comparison was performed within Family 714 and a similar trend was demonstrated. This therefore, supports, the idea that the majority of genetically affected hypertrophic cardiomyopathy patients express left ventricular hypertrophy at different degrees of severity and that abnormalities may sometimes be detected only by comparison with non-affected subjects within the same family but not by our current echocardiographic criteria.
The cause of the absence of definite left ventricular hypertrophy in these subjects (thickness affected about half the cohort with left ventricular hypertrophy) remains unknown, but does not seem to be the consequence of variations in parameters which influence wall thickness, such as blood pressure (Table 5 ). However, the ultrasonic phenotype of hypertrophic cardiomyopathy is not only determined by the causal mutation, but also widely influenced by other genetic factors (modifying genes) such as I/D polymorphism of the angiotensin converting enzyme gene [42] by the wild allele of the morbid gene or by unknown environmental factors, all parameters which were not studied in the current work.
Physiopathological implications
Although results must be interpreted with caution due to the relatively small number of individuals studied, all differences tend in the same direction; left ventricular wall thickness and left atrial volume are increased and left ventricular volume is decreased in patients. These slight differences may reflect an early stage of the disease, suggesting that the phenotype of hypertrophic cardiomyopathy is a continuum from normal structure to typical hypertrophy. It is interesting to note that these individuals were asymptomatic while further studies are needed to determine if they carry a lower risk than those with typical hypertrophy and whether or not they should be treated.
Observations of myosin mutations in hypertrophic cardiomyopathy have led to speculation that the clinical and pathological features of hypertrophic cardiomyopathy (ventricular hypertrophy, myocellular disarray and myocardial scarring) are secondary phenomena resulting from abnormal myofibrillar assembly and reduce force generation [37] . In vitro analyses have shown that some of the mutations described in the -MHC gene induce a decrease in both actin-activated ATPase activity of myosin fragments and the actin translocation rate on the mutated myosin bound to a coverslip surface [38, 39] . The differences pointed out by the current study might support that concept at the organ level: a decrease in left ventricular pump function -as suggested by a similar fractional shortening despite a decrease in wall stress compared to normal subjects -might induce left ventricular hypertrophy which decreases left ventricular cavity size; diastolic dysfunction may be suggested by left atrial volume distension (Table 5 ), but interpretation must be cautious as the E/A ratio and isovolumic relaxation time did not 
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change. Interestingly, similar abnormalities were found in this study for the -MHC gene and the My-BPC gene mutations.
Malformation of the mitral apparatus in hypertrophic cardiomyopathy consists mainly of systolic anterior motion of the valve due to leaflet elongation and malposition or anomalous insertion of papillary muscles [40, 41] . Systolic anterior motion was never observed in affected subjects without left ventricular hypertrophy and leaflet length measurements did not help to identify affected subjects without left ventricular hypertrophy, suggesting that leaflet elongation and systolic anterior motion represent only a secondary phenomenon consecutive to change in left ventricular cavity shape due to left ventricular hypertrophy.
Limitations of the study
Differences between patients without left ventricular hypertrophy and unaffected matched subjects are small and values remain within normal ranges (Fig. 2) . However, by definition, the patients studied here have no overt hypertrophy and the fact that the absolute values are in the normal range derives from the design of our study. Our purpose was to try to identify subtle differences in this particular subgroup of genetically affected subjects, as compared to non-affected individuals. We believe that a difference of 1 mm in wall thickness is relevant in such a subgroup of patients, as 50% of these genetically affected patients demonstrate ECG abnormalities despite the absence of hypertrophy and clinical symptoms.
Although the precise junction of leaflet and chordae is not ideally defined by transthoracic echocardiography, a consistent technique was used here for measurement; furthermore, the average leaflet lengths in the normal group agree with those reported in the literature [40] and elongated leaflets have been described with a comparable prevalence in pathological studies of hypertrophic cardiomyopathy patients [41] These results obtained in two large kindred cannot be extended to all gene mutations encoding for hypertrophic cardiomyopathy, although here results were similar for two different morbid genes. In particular, they cannot be used in clinical practice at the individual level for distinction between genotypically affected and non-affected subjects. Moreover, this study does not eliminate the possibility of strictly normal echocardiograms in subjects with a mutation for hypertrophic cardiomyopathy. Finally, despite its limitations, echocardiography will continue to play an indispensable role in the screening of familial hypertrophic cardiomyopathy due to the genetic heterogeneity of the disease. As genetic defects identified to date probably account for less than one third of the cases of hypertrophic cardiomyopathy [18] , routine genetic screening remains problematic in familial hypertrophic cardiomyopathy [1] .
Conclusions
This study in two families linked to different morbid genes demonstrates that genotypically affected subjects without definite left ventricular hypertrophy -or with an apparently normal echocardiographic examinationmay demonstrate subtle ultrasonic differences in left heart structure or function which can only be revealed by comparison with normal first-degree relatives. This finding has important pathophysiological implications and suggests that the phenotype of familial hypertrophic cardiomyopathy is a continuum from normality to typical left ventricular hypertrophy. Further studies are needed to determine whether these individuals carry the same risk of disease-related death as those with typical hypertrophy and whether or not they should be treated.
